Virios therapeutics' study featured in peer-reviewed journal publication highlighting association of herpes simplex type 1 viral infection with common gastrointestinal disorders, including in patients with comorbid fibromyalgia

Atlanta--(business wire)---- $viri #biotech--virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced the results of a pilot study performed at the university of alabama, titled “gastric herpes simplex virus type 1 infection is associated with functional gastrointestinal disorders in the presence and absence of comorbid fibromyalgia: a pilot case-co
VIRI Ratings Summary
VIRI Quant Ranking